Jade Biosciences JBIO
NASDAQ JBIO
$15.10 +0.24 (+1.62%)
As of: Oct 21, 2026 · 3:59 PM EDT

Jade Biosciences (JBIO) Convertible Debt (2024)

Updated

Jade Biosciences' Convertible Debt was $107.6 million in Q4 2024.

Analysis

Jade Biosciences (JBIO) Convertible Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Jade Biosciences 925.91 Mn -381.71 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 107.60 Mn
API Access

Jade Biosciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=JBIO&period=max&api_key=YOUR_API_KEY